Depression-like effect of prenatal buprenorphine exposure in rats

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Hung, Chih Jen ^a,b   Wu, Chih Cheng ^a,c   Chen, Wen Ying ^d   Chang, Cheng Yi ^e   Kuan, Yu Hsiang ^f   Pan, Hung Chuan ^a,g   Liao, Su Lan ^a   Chen, Chun Jung ^a,b,d,h  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c PROVIDENCE UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e FENG YUAN HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN PROTEIN; BUPRENORPHINE; CATALASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMIPRAMINE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTRANSMITTER; NEUROTROPHIN; SEROTONIN; TROPOMYOSIN RELATED KINASE RECEPTOR TYPE B; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; FEMALE; FORCED SWIM TEST; MALE; MORRIS WATER MAZE TEST; NEWBORN; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; POSITIVE FEEDBACK; PRENATAL EXPOSURE; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; BUPRENORPHINE; CATALASE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84893187642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082262     Document Type: Article

References (41)

1. Jarvis MAE, Schnoll SH (1994) Methadone treatment during pregnancy. J Psychoactive Drugs 26: 155-161. (Pubitemid 24218154)
2. Velez M, Jansson LM, Schroeder J, Williams E (2009) Prenatal methadone exposure and neonatal neurobehavioral functioning. Ped Res 66: 704-709.
3. Walsh SL, Eissenberg T (2003) The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 70 (Suppl 2): S13-S27. (Pubitemid 36556057)
4. Alto WA, O'Connor AB (2011) Management of women treated with buprenorphine during pregnancy. Am J Obst Gynecol 205: 302-308.
5. Farid WO, Dunlop SA, Tait RJ, Hulse GK (2008) The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 6: 125-150. (Pubitemid 352024797)
6. Kakko J, Hellig M, Sarman I (2008) Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 96: 69-78.
7. Lund IO, Fisher G, Welle-Strand GK, O'Grady KE, Debelak K, et al. (2013) A comparison of buprenorphine+naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 7: 61-74.
8. Marquez P, Baliram R, Kieffer BL, Lutfy K (2007) The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52: 1336-1341. (Pubitemid 46601527)
9. Blandthorn J, Forster DA, Love V (2011) Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit. Women Birth 24: 32-39.
10. Coyle MG, Salisbury AL, Lester BM, Jones HE, LinH, et al. (2012) Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 107 (Suppl 1): 63-73.
11. Jansson LM, DiPietro JA, Velez M, Elko A, Williams E, et al. (2011) Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 33: 240-243.
12. Pettit AS, DesRoches R, Bennett SAL (2012) The opiate analgesic buprenorphine decreases proliferation of adult hippocampal neuroblasts and increases survival of their progeny. Neuroscience 200: 211-222.
13. Robinson SE (2002) Effects of buprenorphine and methadone exposures on striatal cholinergic ontogeny. Neurotoxicol Teratol 24: 137-142.
14. Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C (2008) Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 56: 1017-1027.
15. Wu VW, Mo Q, Yabe T, Schwartz JP, Robinson SE (2001) Perinatal opioids reduce striatal nerve growth factor content in rat striatum. Eur J Pharmacol 414: 211-214. (Pubitemid 32181888)
16. Malanga CJ, Kososfsky BE (1999) Mechanisms of action of drugs of abuse on the developing fetal brain. Clin Perinatal 26: 17-37.
17. Englberger W, Kögel B, Friderichs E, Strabburger W, Germann T (2006) Reversibility of opioid receptor occupancy of buprenorphine in vivo. Eur J Pharmacol 534: 95-102. (Pubitemid 43384188)
18. Rounsaville B, Weissman M, Crits-Christoph K, Wilber C, Kleber H (1982) Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry 39: 151-156. (Pubitemid 12178987)
19. Li J, Geng D, Xu J, Weng LJ, Liu Q, et al. (2013) Antidepressant-like effect of macranthol isolated from Illicium dunnianum tutch in mice. Eur J Pharmacol 707: 112-119.
20. Xuan A, Long D, Li J, Ji W, Hong L, et al. (2012) Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci 90: 463-468.
21. Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, et al. (2011) Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS ONE 6: e28451.
22. Liebenberg N, Müller HK, Fischer CW, Harvey BH, Brink CB, et al. (2011) An inhibitor of cAMP-dependent protein kinase induces behavioral and neurological antidepressant-like effects in rats. Neurosci Lett 498: 158-161.
23. Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, et al. (2011) Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 221: 166-171.
24. Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM (2013) Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatr Res 206: 213-216.
25. Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11: 851-876.
26. Hariri AR, Holmes A (2006) Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 10: 182-191.
27. Dwivedi Y, Pandey GN (2008) Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr Dis Treat 4: 161-176. (Pubitemid 351460987)
28. Qi X, Lin W, Li J, Li H, Wang W, et al. (2008) Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depression-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 31: 278-285.
29. Patapoutian A, Reichard LF (2001) Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11: 272-280. (Pubitemid 32524091)
30. Zhang LL, Wang JJ, Liu Y, Lu XB, Kuang Y, et al. (2011) GPR26-deficient mice display increased anxiety- and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdal. Neuroscience 196: 203-214.
31. Belmaker RH, Agam G (2008) Major depressive disorder. N Eng J Med 358: 55-68.
32. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455: 894-902.
33. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19: 89-95. (Pubitemid 38316767)
34. Guzmán DC, Vázquez IE, Brizuela NO, Alvarez RG, Mejía GB, et al. (2006) Assessment of oxidative damage induced by acute doses of morphine sulfate in postnatal and adult rat brain. Neurochem Res 31: 549-554. (Pubitemid 43873750)
35. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005) Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136: 29-37. (Pubitemid 40704606)
36. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavior models of depression. J Neurosci 22: 3251-3261. (Pubitemid 35379212)
37. Dwivedi Y, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2002) [(3)H]cAMP binding sites and protein kinase A activity in the prefrontal cortex of suicide victims. Am J Psychiatry 159: 66-73. (Pubitemid 41070729)
38. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, et al. (2001) Reduced activation and expression of ERK1/2 MAP kinase in the postmortem brain of depressed suicide subjects. J Neurochem 77: 916-928. (Pubitemid 32466788)
39. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, et al. (2007) Cyclic AMP response element-binding protein in postmortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus. Int J Neuropsychopharmacol 10: 621-629. (Pubitemid 47517519)
40. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, et al. (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58: 115-134.
41. Lesch KP (2001) Serotonergic gene expression and depression: implications for developing novel antidepressants. J Affect Dis 62: 57-76. (Pubitemid 32126612)